Signaturefd LLC Has $1.46 Million Holdings in Cencora, Inc. $COR

Key Points

• Signaturefd LLC has increased its holdings in Cencora, Inc. (NYSE:COR) by 29.3%, now owning shares valued at $1.46 million.
• Analyst ratings for Cencora include a consensus rating of "Moderate Buy", with a target price of $311.25, reflecting positive sentiment in the market.
• Insider trading activity revealed that CEO Robert P. Mauch and Chairman Steven H. Collis sold shares totaling nearly $10.6 million recently, indicating a notable decrease in their ownership percentages.

Signaturefd LLC increased its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 29.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,856 shares of the company's stock after purchasing an additional 1,101 shares during the quarter. Signaturefd LLC's holdings in Cencora were worth $1,456,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Patton Fund Management Inc. acquired a new position in Cencora during the 2nd quarter worth $3,378,000. Kathmere Capital Management LLC increased its position in Cencora by 42.3% in the second quarter. Kathmere Capital Management LLC now owns 3,265 shares of the company's stock worth $979,000 after purchasing an additional 970 shares during the period. Perigon Wealth Management LLC increased its position in Cencora by 2.8% in the second quarter. Perigon Wealth Management LLC now owns 2,320 shares of the company's stock worth $696,000 after purchasing an additional 63 shares during the period. Retireful LLC bought a new position in shares of Cencora in the 2nd quarter valued at about $292,000. Finally, TD Private Client Wealth LLC acquired a new position in Cencora in the second quarter valued at approximately $1,663,000. 97.52% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on COR shares. Wells Fargo & Company increased their price objective on shares of Cencora from $337.00 to $354.00 and gave the company an "overweight" rating in a report on Wednesday, August 13th. Morgan Stanley set a $330.00 price objective on Cencora and gave the stock an "equal weight" rating in a research note on Wednesday, July 16th. Finally, Jefferies Financial Group increased their target price on Cencora from $275.00 to $300.00 and gave the company a "hold" rating in a research note on Monday, June 30th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $311.25.

Insider Activity at Cencora

In related news, CEO Robert P. Mauch sold 5,097 shares of the company's stock in a transaction on Thursday, September 18th. The shares were sold at an average price of $290.00, for a total value of $1,478,130.00. Following the completion of the transaction, the chief executive officer directly owned 39,274 shares of the company's stock, valued at approximately $11,389,460. This represents a 11.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the company's stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman directly owned 305,913 shares of the company's stock, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 55,993 shares of company stock worth $16,292,923 over the last 90 days. Corporate insiders own 10.80% of the company's stock.

Cencora Stock Performance

COR stock opened at $306.94 on Monday. The business's 50-day moving average price is $293.00 and its two-hundred day moving average price is $288.82. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. The firm has a market cap of $59.51 billion, a PE ratio of 31.58, a P/E/G ratio of 1.56 and a beta of 0.62. Cencora, Inc. has a 1-year low of $218.65 and a 1-year high of $310.00.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm had revenue of $80.66 billion during the quarter, compared to analysts' expectations of $80.34 billion. During the same period in the previous year, the firm earned $3.34 earnings per share. The company's revenue was up 8.7% on a year-over-year basis. As a group, research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Friday, August 15th were issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.7%. The ex-dividend date was Friday, August 15th. Cencora's dividend payout ratio (DPR) is 22.63%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.